Business
Medicenna Announces Pricing of Marketed Offering of Units
Medicenna Announces Pricing of Marketed Offering of Units Canada NewsWire TORONT...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Announces Pricing of Marketed Offering of Units\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, Oct. 2, 2019\n\n\n\n/NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES./\n TORONTO and HOUSTON, Oct. 2, 2019 /CNW/ - Medicenna Therapeutics Corp. (\"Medicenna\" or the \"Company\") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, is pleased to announce today that it has priced its previously announced marketed offering (the \"Offering\") of units of the Company (\"Units\").  The Company intends to issue Units at a price of CDN$1.30 per Unit. Each Unit is comprised of one common share of the Company (a \"Common Share\") and one-half of one Common Share purchase warrant of the Company (each whole Common Share purchase warrant, a \"Warrant\"). Each Warrant entitles the holder thereof to acquire one Common Share at an exercise price of CDN$1.75 per Common Share for a period of 36 months following the closing of the Offering. In respect of the foregoing, the Company will file an amended and restated preliminary short form prospectus (the \"Amended and Restated Preliminary Prospectus\"). \nThe Offering is undertaken on a best efforts basis in the provinces of British Columbia, Alberta and Ontario through a syndicate of agents (collectively, the \"Agents\") led by Bloom Burton Securities Inc. (the \"Lead Agent\") and including Mackie Research Capital Corporation and Haywood Securities Inc. (together with the Lead Agent, the \"Agents\"). The number of Units to be distributed and the minimum and maximum size of the Offering will be determined by negotiation between the Company and the Lead Agent in the context of the market.\nIn connection with the Offering, the Agents will be paid a cash commission equal to 7.0% of the aggregate gross proceeds of the Offering and will be issued broker warrants exercisable to acquire such number of Common Shares as is equal to 7.0% of the aggregate number of Units sold pursuant to the Offering. T...